Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6791-6801

  Priller, Markus ^a   Pöschl, Julia ^a   Abrão, Leticia ^a   Von Bueren, AndréO ^b   Cho, Yoon Jae ^c   Rutkowski, Stefan ^b   Kretzschmar, Hans A ^a   Schüller, Ulrich ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CASPASE; FORKHEAD BOX M1 PROTEIN; SIOMYCIN A; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; MEDULLOBLASTOMA; MITOSIS SPINDLE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MEDULLOBLASTOMA; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80455162327     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1214     Document Type: Article

References (40)

1. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009;45:992-1005.
2. Ribi K, Relly C, Landolt MA, Alber FD, Boltshauser E, Grotzer MA. Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics 2005;36:357-65. (Pubitemid 43162346)
3. Walker DA, Wilne S. Treatment of medulloblastoma in young children. Lancet Oncol 2005;6:541-2. (Pubitemid 41051917)
4. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004;5:209-18. (Pubitemid 38391216)
5. Cho Y-J, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29:1424-30.
6. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085-8. (Pubitemid 27247016)
7. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-803. (Pubitemid 28217449)
8. Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008;14:123-34.
9. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999;22: 103-14. (Pubitemid 29070097)
10. Choi Y, Borghesani PR, Chan JA, Segal RA. Migration from a mitogenic niche promotes cell-cycle exit. J Neurosci 2005;25:10437-45. (Pubitemid 41628447)
11. Schüller U, Zhao Q, Godinho SA, Heine VM, Medema RH, Pellman D, et al. Forkhead transcription factor FoxM1 regulates mitotic entry and prevents spindle defects in cerebellar granule neuron precursors. Mol Cell Biol 2007;27:8259-70. (Pubitemid 350234238)
12. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005;353:811-22.
13. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002;62:4773-80.
14. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004;18:830-50. (Pubitemid 38480894)
15. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005;25:10875-94. (Pubitemid 41747132)
16. Laoukili J, Kooistra MRH, Bras A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005;7:126-36. (Pubitemid 40268127)
17. Ye H, Holterman AX, Yoo KW, Franks RR, Costa RH. Premature expression of the winged helix transcription factor HFH-11B in regenerating mouse liver accelerates hepatocyte entry into Sphase. Mol Cell Biol 1999;19:8570-80. (Pubitemid 30414050)
18. Wang X, Kiyokawa H, Dennewitz MB, Costa RH. The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci U S A 2002;99:16881-6. (Pubitemid 36034067)
19. Wonsey DR, Follettie MT. Loss of the Forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005;65:5181-9. (Pubitemid 40827327)
20. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, et al. The Forkhead box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 2006;66:2153-61.
21. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 2006;66:1712-20. (Pubitemid 43259956)
22. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 2006;66:3593-602.
23. Schüller U, Kho AT, Zhao Q, Ma Q, Rowitch DH. Cerebellar 'transcriptome' reveals cell-type and stage-specific expression during postnatal development and tumorigenesis. Mol Cell Neurosci 2006;33:247-59. (Pubitemid 44692490)
24. Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial hit '91. Int J Radiat Oncol Biol Phys 2000;46:269-79. (Pubitemid 30067775)
25. Kühl J, Muller HL, Berthold F, Kortmann RD, Deinlein F, Maass E, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klin Padiatr 1998;210:227-33. (Pubitemid 28361244)
26. Rutkowski S, Gerber NU, von Hoff K, Gnekow A, Bode U, Graf N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol 2009; 11:201-10.
27. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon, France: IARC Press; 2007.
28. von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T, et al. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatric Blood Cancer 2010;54:369-76.
29. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.
30. Portugal J, Mansilla S, Bataller M. Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm Des 2010;16:69-78.
31. Castedo M, Perfettini J-L, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-37. (Pubitemid 38638845)
32. Subramaniam D, Ramalingam S, Linehan DC, Dieckgraefe BK, Postier RG, Houchen CW, et al. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. PLoS One 2011;6:e16958.
33. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 2006;66:9731-5. (Pubitemid 44623674)
34. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007;6:1073-85. (Pubitemid 350116703)
35. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009;218:86-94.
36. Ellison DW. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol 2010; 120:305-16.
37. Yang DK, Son CH, Lee SK, Choi PJ, Lee KE, Roh MS. Forkhead boxM1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol 2009;40:464-70.
38. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 2011;17: 1924-34.
39. Adami GR, Ye H. Future roles for FoxM1 inhibitors in cancer treatments. Future Oncol 2007;3:1-3.
40. Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimov AV, et al. Thiazole antibiotics against breast cancer. Cell Cycle 2010;9: 1214-7.